Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42


Sorafenib for patients with differentiated thyroid cancer--authors' reply.

Brose MS, Schlumberger M, Peña C, Kappeler C.

Lancet. 2015 Jan 17;385(9964):228-9. doi: 10.1016/S0140-6736(15)60056-3. No abstract available.


Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.

N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.


Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Epub 2015 Jan 20. Review. No abstract available.


BRAF mutation and thyroid cancer recurrence.

Yarchoan M, LiVolsi VA, Brose MS.

J Clin Oncol. 2015 Jan 1;33(1):7-8. doi: 10.1200/JCO.2014.59.3657. Epub 2014 Nov 24. No abstract available.


A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.

Thyroid. 2014 Oct;24(10):1508-14. doi: 10.1089/thy.2014.0125. Epub 2014 Aug 27.


Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials.

Cohen AB, Brose MS.

J Clin Endocrinol Metab. 2014 Jun;99(6):1995-7. doi: 10.1210/jc.2014-2236. No abstract available.


Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators.

Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.


Management of sorafenib-related adverse events: a clinician's perspective.

Brose MS, Frenette CT, Keefe SM, Stein SM.

Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.


Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ.

J Clin Oncol. 2014 Jan 10;32(2):129-60. doi: 10.1200/JCO.2013.53.7076. Epub 2013 Dec 10.


Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.


Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.


Physician and stakeholder perceptions of conflict of interest policies in oncology.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK.

J Clin Oncol. 2013 May 1;31(13):1677-82. doi: 10.1200/JCO.2012.47.5475. Epub 2013 Mar 25.


Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.

Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ.

J Clin Oncol. 2013 Jan 1;31(1):131-61. doi: 10.1200/JCO.2012.47.1938. Epub 2012 Dec 3. No abstract available. Erratum in: J Clin Oncol. 2013 Jun 1;31(16):2063.


Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.

Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1137-47. doi: 10.1586/era.12.96.


RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL.

Endocr Relat Cancer. 2012 Jul 22;19(4):575-88. doi: 10.1530/ERC-12-0086. Print 2012 Aug.


Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.

J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.


In search of a real "targeted" therapy for thyroid cancer.

Brose MS.

Clin Cancer Res. 2012 Apr 1;18(7):1827-9. doi: 10.1158/1078-0432.CCR-12-0153. Epub 2012 Mar 26.


Targeted inhibition of CD133+ cells in oral cancer cell lines.

Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO, DiRienzo JM.

J Dent Res. 2011 May;90(5):638-45. doi: 10.1177/0022034510393511. Epub 2011 Jan 10.


The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.

Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C, Rothstein JL, May MJ.

Oncogene. 2011 Jan 6;30(1):87-96. doi: 10.1038/onc.2010.396. Epub 2010 Sep 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk